Xilio Therapeutics (XLO) Liabilities and Shareholders Equity (2020 - 2026)

Xilio Therapeutics has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $163.5 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $163.5 million, up 57.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $585.7 million (up 72.6% YoY), and the FY2025 annual result was $154.7 million, up 117.64% from the prior year.
• Liabilities and Shareholders Equity came in at $163.5 million for Q1 2026 at Xilio Therapeutics, up from $154.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $196.4 million in Q1 2022 to a low of $60.9 million in Q4 2023.
• The 5-year median for Liabilities and Shareholders Equity is $111.5 million (2023), against an average of $118.9 million.
• Across the five-year window, Liabilities and Shareholders Equity sank 56.22% in 2023 and surged 117.64% in 2025, its largest moves.
• Xilio Therapeutics' Liabilities and Shareholders Equity stood at $139.2 million in 2022, then tumbled by 56.22% to $60.9 million in 2023, then increased by 16.66% to $71.1 million in 2024, then soared by 117.64% to $154.7 million in 2025, then rose by 5.69% to $163.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $163.5 million (Q1 2026), $154.7 million (Q4 2025), and $133.7 million (Q3 2025), per Business Quant data.